Oppenheimer believes data presented at the Triple meeting are positive for Amgen’s (AMGN) program, AMG 193, and for the PRMT5 class, including Ideaya Biosciences’ (IDYA) MAT2A plus PRMT5 combination. Amgen and Ideaya are exploring lower doses in the combo, which is expected to maximize pathway suppression, while optimizing overall tolerability, says the analyst, who contends that “there’s a compelling rationale for any of BMY/MRTX, AMGN, or TNGX, to combine with MAT2A,” enhancing the overall value proposition for Ideaya. The firm has an Outperform rating and $35 price target on Ideaya shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IDYA:
- Ideaya Biosciences selects Werner Helicase Inhibitor Development DC with GSK
- Ideaya Biosciences participates in a conference call with JPMorgan
- Ideaya Biosciences granted IDE161 fast track designation in second indication
- Ideaya Biosciences granted Fast Track designation for IDE161 program by FDA
- Ideaya Biosciences initiates monotherapy expansion in IDE161 trial